NURS8024 PHARMACOLOGY EXAM 1 ACTUAL VERIFIED EXAM | HIGHER EDUCATION ADVANCED NURSING
2026/2027 ACADEMIC YEAR | VERIFIED Q&A | GRADUATE-LEVEL NURSING & ADVANCED PRACTICE
NURS8024
PHARM EXAM 1
2026/2027
NURS8024 Pharmacology Exam 1 Actual Verified
Higher Education Advanced Nursing Curriculum
2026/2027 Academic Year | Verified Q&A for Graduate-Level Nursing
and Advanced Practice Students | Pharmacology Exam 1
150Q VERIFIED NEWEST EXAM RATIONALES
ACTUAL EXAM 2026/2027 ADV PHARM
INCLUDES:
• Pharmacokinetics, Pharmacodynamics, Autonomic, Cardio, Neuro Pharm
• Antibiotics, Endocrine, Psych, Pain, Anti-inflammatory, Prescribing
• 150 Verified Questions + Answers + Detailed Rationales | Exam 1
• Professional Study Guide | Borders + Page Numbers | 2026/2027 Edition
NURS8024 Pharmacology Exam 1 | Advanced Nursing | Not affiliated
Confidential Study Guide - Educational Purposes Only | 2026/2027 Edition
,Pharmacokinetic Pharmacodynamic Principles Autonomic Pharmacology
Description: Pharmacokinetics ADME Absorption process drug enters circulation routes oral enteral bioavailability fraction reaches systemic circulation 0-100% affected
first-pass hepatic metabolism food, parenteral IV 100% IM subcut, Distribution reversible transfer blood to tissues factors protein binding albumin alpha1-acid glycoprotein
free drug active, volume of distribution Vd = dose / plasma concentration high Vd tissue bound low Vd blood bound, barriers blood-brain placenta, Metabolism
biotransformation liver main Phase I oxidation reduction hydrolysis CYP450 system CYP1A2 2C9 2C19 2D6 3A4 inducers inhibitors, Phase II conjugation glucuronidation
acetylation, prodrugs, first-pass, Excretion elimination kidney main glomerular filtration tubular secretion reabsorption, half-life t1/2 time 50% eliminated 4-5 half-lives steady
state, clearance, pharmacodynamics action drug on body receptor theory receptors proteins, agonist full partial inverse, antagonist competitive non-competitive,
dose-response relationship efficacy maximal effect potency amount needed ED50 effective dose 50% population, LD50 lethal dose, therapeutic index TI = LD50/ED50 wide
narrow safety, therapeutic window, receptor regulation up down regulation desensitization, autonomic pharmacology ANS autonomic nervous system SNS sympathetic
thoracolumbar fight flight neurotransmitter norepinephrine epinephrine receptors adrenergic alpha1 vasoconstriction alpha2 feedback beta1 heart kidney beta2
bronchodilation, drugs direct indirect agonists antagonists phenylephrine alpha1 clonidine alpha2 dobutamine beta1 albuterol beta2, PNS parasympathetic craniosacral
rest digest acetylcholine receptors cholinergic nicotinic Nm muscle Ng ganglia muscarinic M1 M2 M3, drugs cholinomimetics bethanechol muscarinic neostigmine indirect
anticholinesterase, anticholinergics atropine scopolamine.
Cardiovascular Neuro Antimicrobial Pharmacology Advanced
Description: Cardiovascular pharmacology antihypertensives classes mechanism diuretics thiazide hydrochlorothiazide Na Cl reabsorption loop furosemide K-sparing
spironolactone, ACE inhibitors ACE converts Ang I to II -pril lisinopril enalapril side cough hyperkalemia, ARBs Angiotensin Receptor Blockers -sartan losartan valsartan no
cough, calcium channel blockers CCB dihydropyridine -dipine amlodipine vasodilation non-dihydropyridine verapamil diltiazem heart, beta blockers -olol metoprolol atenolol
propranolol, central alpha2 agonists clonidine, vasodilators hydralazine, heart failure drugs HFrEF GDMT Guideline Directed Medical Therapy ACE/ARNI ARB neprilysin
sacubitril valsartan beta blocker MRA mineralocorticoid spironolactone SGLT2 dapagliflozin diuretics inotrope digoxin, antiarrhythmics Vaughan Williams I Na block II beta
blocker III K block amiodarone IV Ca block, anticoagulants heparin warfarin DOAC apixaban, antilipemics statins -statin, neuro pharmacology antiepileptics mechanism Na
channel block phenytoin carbamazepine lamotrigine, Ca channel ethosuximide absence, GABA enhance valproate phenobarbital benzodiazepines, glutamate block,
Parkinson disease dopamine deficiency levodopa precursor + carbidopa peripheral decarboxylase inhibitor prevents conversion, dopamine agonists pramipexole COMT
inhibitors MAO-B inhibitors amantadine anticholinergics, Alzheimer cholinesterase inhibitors donepezil rivastigmine galantamine NMDA antagonist memantine,
antimicrobials antibiotics classification cell wall synthesis inhibitors beta-lactams penicillins amoxicillin piperacillin cephalosporins generations ceftriaxone, glycopeptide
vancomycin cell wall, protein synthesis 30S tetracyclines aminoglycosides -mycin -micin ototoxic nephrotoxic, 50S macrolides -thromycin azithromycin chloramphenicol
clindamycin linezolid, DNA synthesis fluoroquinolones -floxacin ciprofloxacin levofloxacin tendon rupture, folate antimetabolites TMP-SMX, resistance mechanisms
enzymatic destruction beta-lactamase efflux pump target modification.
Endocrine Psych Pain Prescribing Advanced Nursing Pharm Exam 1
Description: Endocrine pharmacology diabetes mellitus Type 1 absolute insulin deficiency Type 2 insulin resistance, insulin classification rapid lispro aspart onset 15 min
short regular 30 min intermediate NPH 1-2 hr long glargine detemir no peak ultra-long degludec, administration sliding scale basal bolus, oral antihyperglycemics metformin
biguanide first-line decreases hepatic gluconeogenesis lactic acidosis, sulfonylureas -ide glipizide glimepiride stimulate insulin hypoglycemia, meglitinides -glinide,
thiazolidinediones -glitazone pioglitazone PPAR, DPP-4 inhibitors -gliptin sitagliptin, SGLT2 inhibitors -flozin empagliflozin, GLP-1 agonists -tide liraglutide semaglutide,
thyroid hypothyroidism levothyroxine T4 replacement narrow TI, hyperthyroidism antithyroid methimazole propylthiouracil PTU blocks synthesis, adrenal glucocorticoids
hydrocortisone prednisone dexamethasone anti-inflammatory immunosuppressive HPA suppression Cushing, mineralocorticoid fludrocortisone, psych pharmacology
antidepressants monoamine hypothesis SSRI Selective Serotonin Reuptake Inhibitor -pram citalopram escitalopram fluoxetine sertraline paroxetine first-line, SNRI
venlafaxine duloxetine dual, TCA tricyclic -triptyline amitriptyline nortriptyline anticholinergic cardiotoxic, MAOI monoamine oxidase inhibitor phenelzine tranylcypromine
tyramine crisis hypertensive, antipsychotics schizophrenia dopamine hypothesis typical first-generation haloperidol chlorpromazine EPS extrapyramidal, atypical
second-generation clozapine olanzapine risperidone quetiapine metabolic syndrome, anxiolytics benzodiazepines -azepam diazepam lorazepam alprazolam GABA-A
dependence, buspirone non-benzo, pain anti-inflammatory analgesics pain pathway, opioids mu kappa delta receptors full agonist morphine fentanyl oxycodone
hydrocodone side effects respiratory depression sedation constipation miosis tolerance dependence reversal naloxone, NSAIDs Non-Steroidal Anti-Inflammatory Drugs
COX-1 COX-2 inhibitor ibuprofen naproxen ketorolac bleeding renal GI, selective COX-2 celecoxib, acetaminophen central analgesic hepatotoxic, adjuvants gabapentin
neuropathic, prescribing principles 5 rights right patient drug dose route time, DEA Drug Enforcement Administration schedules I no medical use high abuse heroin LSD II
high abuse medical use oxycodone morphine fentanyl cocaine III-V decreasing abuse, prescription writing controlled substance agreement, patient factors age pediatric
geriatric Beers criteria, renal hepatic dose adjustment, pregnancy FDA former categories teratogenic, pharmacogenomics CYP polymorphisms, NURS8024 Pharmacology
Exam 1 advanced nursing.
Page 2 - NURS8024 Pharm Exam1 150Q 2026/2027
,Question 1: Q1: Pharmacokinetics - ADME principles and bioavailability?
A. Pharmacokinetics ADME Absorption bioavailability first-pass, Distribution protein binding Vd, Metabolism CYP450 Phase I II, Excretion kidney
glomerular filtration
B. No ADME pharmacokinetics
C. Only Absorption ADME
D. Only Excretion ADME
CORRECT ANSWER: A. Pharmacokinetics ADME Absorption bioavailability first-pass, Distribution protein binding Vd, Metabolism CYP450
Phase I II, Excretion kidney glomerular filtration
RATIONALE:
Rationale: Pharmacokinetics ADME Absorption bioavailability first-pass, Distribution protein binding Vd, Metabolism CYP450 Phase I II, Excretion kidney glomerular
filtration. Per NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for graduate-level nursing and advanced practice
students exam 1 2026/2027.
Question 2: Q2: Pharmacodynamics - receptor binding dose-response?
A. No dose-response pharmacodynamics
B. No receptor pharmacodynamics
C. Pharmacodynamics receptor agonist antagonist partial, dose-response efficacy potency ED50 LD50 therapeutic index TI = LD50/ED50, therapeutic
window
D. No therapeutic index pharmacodynamics
CORRECT ANSWER: C. Pharmacodynamics receptor agonist antagonist partial, dose-response efficacy potency ED50 LD50 therapeutic index
TI = LD50/ED50, therapeutic window
RATIONALE:
Rationale: Pharmacodynamics receptor agonist antagonist partial, dose-response efficacy potency ED50 LD50 therapeutic index TI = LD50/ED50, therapeutic window.
Per NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for graduate-level nursing and advanced practice students
exam 1 2026/2027.
Question 3: Q3: Autonomic pharmacology - sympathetic vs parasympathetic?
A. PNS adrenergic autonomic pharm
B. SNS cholinergic autonomic pharm
C. No SNS PNS autonomic pharm
D. Autonomic SNS sympathetic adrenergic alpha beta fight flight epinephrine norepinephrine, PNS parasympathetic cholinergic rest digest acetylcholine
muscarinic nicotinic
CORRECT ANSWER: D. Autonomic SNS sympathetic adrenergic alpha beta fight flight epinephrine norepinephrine, PNS parasympathetic
cholinergic rest digest acetylcholine muscarinic nicotinic
RATIONALE:
Rationale: Autonomic SNS sympathetic adrenergic alpha beta fight flight epinephrine norepinephrine, PNS parasympathetic cholinergic rest digest acetylcholine
muscarinic nicotinic. Per NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for graduate-level nursing and
advanced practice students exam 1 2026/2027.
Question 4: Q4: Cardiovascular pharmacology - antihypertensives and heart failure drugs?
A. No antihypertensives cardiovascular pharm
B. Cardiovascular antihypertensives ACE inhibitors -pril ARBs -sartan CCB -dipine diuretics thiazide beta blockers -olol, heart failure ACE diuretics
digoxin
C. Only ACE inhibitors cardiovascular pharm
D. No heart failure drugs cardiovascular pharm
CORRECT ANSWER: B. Cardiovascular antihypertensives ACE inhibitors -pril ARBs -sartan CCB -dipine diuretics thiazide beta blockers -olol,
heart failure ACE diuretics digoxin
RATIONALE:
Rationale: Cardiovascular antihypertensives ACE inhibitors -pril ARBs -sartan CCB -dipine diuretics thiazide beta blockers -olol, heart failure ACE diuretics digoxin. Per
NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for graduate-level nursing and advanced practice students
exam 1 2026/2027.
Question 5: Q5: Neuro pharmacology - antiepileptics Parkinson Alzheimer?
A. Neuro antiepileptics phenytoin carbamazepine valproate mechanism Na channel GABA, Parkinson levodopa carbidopa dopamine agonists, Alzheimer
donepezil cholinesterase
B. No antiepileptics neuro pharm
C. No Parkinson drugs neuro pharm
D. No Alzheimer drugs neuro pharm
CORRECT ANSWER: A. Neuro antiepileptics phenytoin carbamazepine valproate mechanism Na channel GABA, Parkinson levodopa
carbidopa dopamine agonists, Alzheimer donepezil cholinesterase
RATIONALE:
Rationale: Neuro antiepileptics phenytoin carbamazepine valproate mechanism Na channel GABA, Parkinson levodopa carbidopa dopamine agonists, Alzheimer
donepezil cholinesterase. Per NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for graduate-level nursing and
advanced practice students exam 1 2026/2027.
Question 6: Q6: Antibiotics - classes mechanisms resistance?
A. No resistance antibiotics
B. Only penicillins antibiotics
C. Antibiotics classes penicillins beta-lactam cell wall cephalosporins, protein synthesis tetracyclines macrolides aminoglycosides, DNA fluoroquinolones,
resistance mechanisms beta-lactamase
D. Only protein synthesis antibiotics
Page 3 - NURS8024 Pharm Exam1 150Q 2026/2027
, CORRECT ANSWER: C. Antibiotics classes penicillins beta-lactam cell wall cephalosporins, protein synthesis tetracyclines macrolides
aminoglycosides, DNA fluoroquinolones, resistance mechanisms beta-lactamase
RATIONALE:
Rationale: Antibiotics classes penicillins beta-lactam cell wall cephalosporins, protein synthesis tetracyclines macrolides aminoglycosides, DNA fluoroquinolones,
resistance mechanisms beta-lactamase. Per NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for
graduate-level nursing and advanced practice students exam 1 2026/2027.
Question 7: Q7: Endocrine pharmacology - diabetes thyroid adrenal?
A. No thyroid endocrine pharm
B. Only insulin endocrine pharm
C. No adrenal endocrine pharm
D. Endocrine diabetes insulin types rapid short intermediate long, oral metformin sulfonylureas, thyroid levothyroxine antithyroid methimazole, adrenal
steroids
CORRECT ANSWER: D. Endocrine diabetes insulin types rapid short intermediate long, oral metformin sulfonylureas, thyroid levothyroxine
antithyroid methimazole, adrenal steroids
RATIONALE:
Rationale: Endocrine diabetes insulin types rapid short intermediate long, oral metformin sulfonylureas, thyroid levothyroxine antithyroid methimazole, adrenal steroids.
Per NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for graduate-level nursing and advanced practice students
exam 1 2026/2027.
Question 8: Q8: Psych pharmacology - antidepressants antipsychotics anxiolytics?
A. Only SSRI psych pharm
B. Psych antidepressants SSRI -pram -ine SNRI TCA MAOI mechanism serotonin norepinephrine, antipsychotics typical atypical dopamine blockade,
anxiolytics benzodiazepines GABA
C. No antipsychotics psych pharm
D. No anxiolytics psych pharm
CORRECT ANSWER: B. Psych antidepressants SSRI -pram -ine SNRI TCA MAOI mechanism serotonin norepinephrine, antipsychotics typical
atypical dopamine blockade, anxiolytics benzodiazepines GABA
RATIONALE:
Rationale: Psych antidepressants SSRI -pram -ine SNRI TCA MAOI mechanism serotonin norepinephrine, antipsychotics typical atypical dopamine blockade, anxiolytics
benzodiazepines GABA. Per NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for graduate-level nursing and
advanced practice students exam 1 2026/2027.
Question 9: Q9: Pain and anti-inflammatory - opioids NSAIDs and analgesics?
A. Pain opioids mu receptor agonist morphine fentanyl side effects respiratory depression constipation, NSAIDs COX inhibitor ibuprofen naproxen,
acetaminophen, adjuvants
B. Only opioids pain anti-inflammatory
C. Only NSAIDs pain anti-inflammatory
D. No analgesics pain anti-inflammatory
CORRECT ANSWER: A. Pain opioids mu receptor agonist morphine fentanyl side effects respiratory depression constipation, NSAIDs COX
inhibitor ibuprofen naproxen, acetaminophen, adjuvants
RATIONALE:
Rationale: Pain opioids mu receptor agonist morphine fentanyl side effects respiratory depression constipation, NSAIDs COX inhibitor ibuprofen naproxen,
acetaminophen, adjuvants. Per NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for graduate-level nursing and
advanced practice students exam 1 2026/2027.
Question 10: Q10: Prescribing - principles DEA schedules and patient factors?
A. Only 5 rights prescribing
B. No DEA schedules prescribing
C. Prescribing principles 5 rights, DEA schedules I-V no medical high abuse I, prescription II-V, patient factors age renal hepatic pregnancy
pharmacogenomics
D. No patient factors prescribing
CORRECT ANSWER: C. Prescribing principles 5 rights, DEA schedules I-V no medical high abuse I, prescription II-V, patient factors age renal
hepatic pregnancy pharmacogenomics
RATIONALE:
Rationale: Prescribing principles 5 rights, DEA schedules I-V no medical high abuse I, prescription II-V, patient factors age renal hepatic pregnancy pharmacogenomics.
Per NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for graduate-level nursing and advanced practice students
exam 1 2026/2027.
Page 4 - NURS8024 Pharm Exam1 150Q 2026/2027
2026/2027 ACADEMIC YEAR | VERIFIED Q&A | GRADUATE-LEVEL NURSING & ADVANCED PRACTICE
NURS8024
PHARM EXAM 1
2026/2027
NURS8024 Pharmacology Exam 1 Actual Verified
Higher Education Advanced Nursing Curriculum
2026/2027 Academic Year | Verified Q&A for Graduate-Level Nursing
and Advanced Practice Students | Pharmacology Exam 1
150Q VERIFIED NEWEST EXAM RATIONALES
ACTUAL EXAM 2026/2027 ADV PHARM
INCLUDES:
• Pharmacokinetics, Pharmacodynamics, Autonomic, Cardio, Neuro Pharm
• Antibiotics, Endocrine, Psych, Pain, Anti-inflammatory, Prescribing
• 150 Verified Questions + Answers + Detailed Rationales | Exam 1
• Professional Study Guide | Borders + Page Numbers | 2026/2027 Edition
NURS8024 Pharmacology Exam 1 | Advanced Nursing | Not affiliated
Confidential Study Guide - Educational Purposes Only | 2026/2027 Edition
,Pharmacokinetic Pharmacodynamic Principles Autonomic Pharmacology
Description: Pharmacokinetics ADME Absorption process drug enters circulation routes oral enteral bioavailability fraction reaches systemic circulation 0-100% affected
first-pass hepatic metabolism food, parenteral IV 100% IM subcut, Distribution reversible transfer blood to tissues factors protein binding albumin alpha1-acid glycoprotein
free drug active, volume of distribution Vd = dose / plasma concentration high Vd tissue bound low Vd blood bound, barriers blood-brain placenta, Metabolism
biotransformation liver main Phase I oxidation reduction hydrolysis CYP450 system CYP1A2 2C9 2C19 2D6 3A4 inducers inhibitors, Phase II conjugation glucuronidation
acetylation, prodrugs, first-pass, Excretion elimination kidney main glomerular filtration tubular secretion reabsorption, half-life t1/2 time 50% eliminated 4-5 half-lives steady
state, clearance, pharmacodynamics action drug on body receptor theory receptors proteins, agonist full partial inverse, antagonist competitive non-competitive,
dose-response relationship efficacy maximal effect potency amount needed ED50 effective dose 50% population, LD50 lethal dose, therapeutic index TI = LD50/ED50 wide
narrow safety, therapeutic window, receptor regulation up down regulation desensitization, autonomic pharmacology ANS autonomic nervous system SNS sympathetic
thoracolumbar fight flight neurotransmitter norepinephrine epinephrine receptors adrenergic alpha1 vasoconstriction alpha2 feedback beta1 heart kidney beta2
bronchodilation, drugs direct indirect agonists antagonists phenylephrine alpha1 clonidine alpha2 dobutamine beta1 albuterol beta2, PNS parasympathetic craniosacral
rest digest acetylcholine receptors cholinergic nicotinic Nm muscle Ng ganglia muscarinic M1 M2 M3, drugs cholinomimetics bethanechol muscarinic neostigmine indirect
anticholinesterase, anticholinergics atropine scopolamine.
Cardiovascular Neuro Antimicrobial Pharmacology Advanced
Description: Cardiovascular pharmacology antihypertensives classes mechanism diuretics thiazide hydrochlorothiazide Na Cl reabsorption loop furosemide K-sparing
spironolactone, ACE inhibitors ACE converts Ang I to II -pril lisinopril enalapril side cough hyperkalemia, ARBs Angiotensin Receptor Blockers -sartan losartan valsartan no
cough, calcium channel blockers CCB dihydropyridine -dipine amlodipine vasodilation non-dihydropyridine verapamil diltiazem heart, beta blockers -olol metoprolol atenolol
propranolol, central alpha2 agonists clonidine, vasodilators hydralazine, heart failure drugs HFrEF GDMT Guideline Directed Medical Therapy ACE/ARNI ARB neprilysin
sacubitril valsartan beta blocker MRA mineralocorticoid spironolactone SGLT2 dapagliflozin diuretics inotrope digoxin, antiarrhythmics Vaughan Williams I Na block II beta
blocker III K block amiodarone IV Ca block, anticoagulants heparin warfarin DOAC apixaban, antilipemics statins -statin, neuro pharmacology antiepileptics mechanism Na
channel block phenytoin carbamazepine lamotrigine, Ca channel ethosuximide absence, GABA enhance valproate phenobarbital benzodiazepines, glutamate block,
Parkinson disease dopamine deficiency levodopa precursor + carbidopa peripheral decarboxylase inhibitor prevents conversion, dopamine agonists pramipexole COMT
inhibitors MAO-B inhibitors amantadine anticholinergics, Alzheimer cholinesterase inhibitors donepezil rivastigmine galantamine NMDA antagonist memantine,
antimicrobials antibiotics classification cell wall synthesis inhibitors beta-lactams penicillins amoxicillin piperacillin cephalosporins generations ceftriaxone, glycopeptide
vancomycin cell wall, protein synthesis 30S tetracyclines aminoglycosides -mycin -micin ototoxic nephrotoxic, 50S macrolides -thromycin azithromycin chloramphenicol
clindamycin linezolid, DNA synthesis fluoroquinolones -floxacin ciprofloxacin levofloxacin tendon rupture, folate antimetabolites TMP-SMX, resistance mechanisms
enzymatic destruction beta-lactamase efflux pump target modification.
Endocrine Psych Pain Prescribing Advanced Nursing Pharm Exam 1
Description: Endocrine pharmacology diabetes mellitus Type 1 absolute insulin deficiency Type 2 insulin resistance, insulin classification rapid lispro aspart onset 15 min
short regular 30 min intermediate NPH 1-2 hr long glargine detemir no peak ultra-long degludec, administration sliding scale basal bolus, oral antihyperglycemics metformin
biguanide first-line decreases hepatic gluconeogenesis lactic acidosis, sulfonylureas -ide glipizide glimepiride stimulate insulin hypoglycemia, meglitinides -glinide,
thiazolidinediones -glitazone pioglitazone PPAR, DPP-4 inhibitors -gliptin sitagliptin, SGLT2 inhibitors -flozin empagliflozin, GLP-1 agonists -tide liraglutide semaglutide,
thyroid hypothyroidism levothyroxine T4 replacement narrow TI, hyperthyroidism antithyroid methimazole propylthiouracil PTU blocks synthesis, adrenal glucocorticoids
hydrocortisone prednisone dexamethasone anti-inflammatory immunosuppressive HPA suppression Cushing, mineralocorticoid fludrocortisone, psych pharmacology
antidepressants monoamine hypothesis SSRI Selective Serotonin Reuptake Inhibitor -pram citalopram escitalopram fluoxetine sertraline paroxetine first-line, SNRI
venlafaxine duloxetine dual, TCA tricyclic -triptyline amitriptyline nortriptyline anticholinergic cardiotoxic, MAOI monoamine oxidase inhibitor phenelzine tranylcypromine
tyramine crisis hypertensive, antipsychotics schizophrenia dopamine hypothesis typical first-generation haloperidol chlorpromazine EPS extrapyramidal, atypical
second-generation clozapine olanzapine risperidone quetiapine metabolic syndrome, anxiolytics benzodiazepines -azepam diazepam lorazepam alprazolam GABA-A
dependence, buspirone non-benzo, pain anti-inflammatory analgesics pain pathway, opioids mu kappa delta receptors full agonist morphine fentanyl oxycodone
hydrocodone side effects respiratory depression sedation constipation miosis tolerance dependence reversal naloxone, NSAIDs Non-Steroidal Anti-Inflammatory Drugs
COX-1 COX-2 inhibitor ibuprofen naproxen ketorolac bleeding renal GI, selective COX-2 celecoxib, acetaminophen central analgesic hepatotoxic, adjuvants gabapentin
neuropathic, prescribing principles 5 rights right patient drug dose route time, DEA Drug Enforcement Administration schedules I no medical use high abuse heroin LSD II
high abuse medical use oxycodone morphine fentanyl cocaine III-V decreasing abuse, prescription writing controlled substance agreement, patient factors age pediatric
geriatric Beers criteria, renal hepatic dose adjustment, pregnancy FDA former categories teratogenic, pharmacogenomics CYP polymorphisms, NURS8024 Pharmacology
Exam 1 advanced nursing.
Page 2 - NURS8024 Pharm Exam1 150Q 2026/2027
,Question 1: Q1: Pharmacokinetics - ADME principles and bioavailability?
A. Pharmacokinetics ADME Absorption bioavailability first-pass, Distribution protein binding Vd, Metabolism CYP450 Phase I II, Excretion kidney
glomerular filtration
B. No ADME pharmacokinetics
C. Only Absorption ADME
D. Only Excretion ADME
CORRECT ANSWER: A. Pharmacokinetics ADME Absorption bioavailability first-pass, Distribution protein binding Vd, Metabolism CYP450
Phase I II, Excretion kidney glomerular filtration
RATIONALE:
Rationale: Pharmacokinetics ADME Absorption bioavailability first-pass, Distribution protein binding Vd, Metabolism CYP450 Phase I II, Excretion kidney glomerular
filtration. Per NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for graduate-level nursing and advanced practice
students exam 1 2026/2027.
Question 2: Q2: Pharmacodynamics - receptor binding dose-response?
A. No dose-response pharmacodynamics
B. No receptor pharmacodynamics
C. Pharmacodynamics receptor agonist antagonist partial, dose-response efficacy potency ED50 LD50 therapeutic index TI = LD50/ED50, therapeutic
window
D. No therapeutic index pharmacodynamics
CORRECT ANSWER: C. Pharmacodynamics receptor agonist antagonist partial, dose-response efficacy potency ED50 LD50 therapeutic index
TI = LD50/ED50, therapeutic window
RATIONALE:
Rationale: Pharmacodynamics receptor agonist antagonist partial, dose-response efficacy potency ED50 LD50 therapeutic index TI = LD50/ED50, therapeutic window.
Per NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for graduate-level nursing and advanced practice students
exam 1 2026/2027.
Question 3: Q3: Autonomic pharmacology - sympathetic vs parasympathetic?
A. PNS adrenergic autonomic pharm
B. SNS cholinergic autonomic pharm
C. No SNS PNS autonomic pharm
D. Autonomic SNS sympathetic adrenergic alpha beta fight flight epinephrine norepinephrine, PNS parasympathetic cholinergic rest digest acetylcholine
muscarinic nicotinic
CORRECT ANSWER: D. Autonomic SNS sympathetic adrenergic alpha beta fight flight epinephrine norepinephrine, PNS parasympathetic
cholinergic rest digest acetylcholine muscarinic nicotinic
RATIONALE:
Rationale: Autonomic SNS sympathetic adrenergic alpha beta fight flight epinephrine norepinephrine, PNS parasympathetic cholinergic rest digest acetylcholine
muscarinic nicotinic. Per NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for graduate-level nursing and
advanced practice students exam 1 2026/2027.
Question 4: Q4: Cardiovascular pharmacology - antihypertensives and heart failure drugs?
A. No antihypertensives cardiovascular pharm
B. Cardiovascular antihypertensives ACE inhibitors -pril ARBs -sartan CCB -dipine diuretics thiazide beta blockers -olol, heart failure ACE diuretics
digoxin
C. Only ACE inhibitors cardiovascular pharm
D. No heart failure drugs cardiovascular pharm
CORRECT ANSWER: B. Cardiovascular antihypertensives ACE inhibitors -pril ARBs -sartan CCB -dipine diuretics thiazide beta blockers -olol,
heart failure ACE diuretics digoxin
RATIONALE:
Rationale: Cardiovascular antihypertensives ACE inhibitors -pril ARBs -sartan CCB -dipine diuretics thiazide beta blockers -olol, heart failure ACE diuretics digoxin. Per
NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for graduate-level nursing and advanced practice students
exam 1 2026/2027.
Question 5: Q5: Neuro pharmacology - antiepileptics Parkinson Alzheimer?
A. Neuro antiepileptics phenytoin carbamazepine valproate mechanism Na channel GABA, Parkinson levodopa carbidopa dopamine agonists, Alzheimer
donepezil cholinesterase
B. No antiepileptics neuro pharm
C. No Parkinson drugs neuro pharm
D. No Alzheimer drugs neuro pharm
CORRECT ANSWER: A. Neuro antiepileptics phenytoin carbamazepine valproate mechanism Na channel GABA, Parkinson levodopa
carbidopa dopamine agonists, Alzheimer donepezil cholinesterase
RATIONALE:
Rationale: Neuro antiepileptics phenytoin carbamazepine valproate mechanism Na channel GABA, Parkinson levodopa carbidopa dopamine agonists, Alzheimer
donepezil cholinesterase. Per NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for graduate-level nursing and
advanced practice students exam 1 2026/2027.
Question 6: Q6: Antibiotics - classes mechanisms resistance?
A. No resistance antibiotics
B. Only penicillins antibiotics
C. Antibiotics classes penicillins beta-lactam cell wall cephalosporins, protein synthesis tetracyclines macrolides aminoglycosides, DNA fluoroquinolones,
resistance mechanisms beta-lactamase
D. Only protein synthesis antibiotics
Page 3 - NURS8024 Pharm Exam1 150Q 2026/2027
, CORRECT ANSWER: C. Antibiotics classes penicillins beta-lactam cell wall cephalosporins, protein synthesis tetracyclines macrolides
aminoglycosides, DNA fluoroquinolones, resistance mechanisms beta-lactamase
RATIONALE:
Rationale: Antibiotics classes penicillins beta-lactam cell wall cephalosporins, protein synthesis tetracyclines macrolides aminoglycosides, DNA fluoroquinolones,
resistance mechanisms beta-lactamase. Per NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for
graduate-level nursing and advanced practice students exam 1 2026/2027.
Question 7: Q7: Endocrine pharmacology - diabetes thyroid adrenal?
A. No thyroid endocrine pharm
B. Only insulin endocrine pharm
C. No adrenal endocrine pharm
D. Endocrine diabetes insulin types rapid short intermediate long, oral metformin sulfonylureas, thyroid levothyroxine antithyroid methimazole, adrenal
steroids
CORRECT ANSWER: D. Endocrine diabetes insulin types rapid short intermediate long, oral metformin sulfonylureas, thyroid levothyroxine
antithyroid methimazole, adrenal steroids
RATIONALE:
Rationale: Endocrine diabetes insulin types rapid short intermediate long, oral metformin sulfonylureas, thyroid levothyroxine antithyroid methimazole, adrenal steroids.
Per NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for graduate-level nursing and advanced practice students
exam 1 2026/2027.
Question 8: Q8: Psych pharmacology - antidepressants antipsychotics anxiolytics?
A. Only SSRI psych pharm
B. Psych antidepressants SSRI -pram -ine SNRI TCA MAOI mechanism serotonin norepinephrine, antipsychotics typical atypical dopamine blockade,
anxiolytics benzodiazepines GABA
C. No antipsychotics psych pharm
D. No anxiolytics psych pharm
CORRECT ANSWER: B. Psych antidepressants SSRI -pram -ine SNRI TCA MAOI mechanism serotonin norepinephrine, antipsychotics typical
atypical dopamine blockade, anxiolytics benzodiazepines GABA
RATIONALE:
Rationale: Psych antidepressants SSRI -pram -ine SNRI TCA MAOI mechanism serotonin norepinephrine, antipsychotics typical atypical dopamine blockade, anxiolytics
benzodiazepines GABA. Per NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for graduate-level nursing and
advanced practice students exam 1 2026/2027.
Question 9: Q9: Pain and anti-inflammatory - opioids NSAIDs and analgesics?
A. Pain opioids mu receptor agonist morphine fentanyl side effects respiratory depression constipation, NSAIDs COX inhibitor ibuprofen naproxen,
acetaminophen, adjuvants
B. Only opioids pain anti-inflammatory
C. Only NSAIDs pain anti-inflammatory
D. No analgesics pain anti-inflammatory
CORRECT ANSWER: A. Pain opioids mu receptor agonist morphine fentanyl side effects respiratory depression constipation, NSAIDs COX
inhibitor ibuprofen naproxen, acetaminophen, adjuvants
RATIONALE:
Rationale: Pain opioids mu receptor agonist morphine fentanyl side effects respiratory depression constipation, NSAIDs COX inhibitor ibuprofen naproxen,
acetaminophen, adjuvants. Per NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for graduate-level nursing and
advanced practice students exam 1 2026/2027.
Question 10: Q10: Prescribing - principles DEA schedules and patient factors?
A. Only 5 rights prescribing
B. No DEA schedules prescribing
C. Prescribing principles 5 rights, DEA schedules I-V no medical high abuse I, prescription II-V, patient factors age renal hepatic pregnancy
pharmacogenomics
D. No patient factors prescribing
CORRECT ANSWER: C. Prescribing principles 5 rights, DEA schedules I-V no medical high abuse I, prescription II-V, patient factors age renal
hepatic pregnancy pharmacogenomics
RATIONALE:
Rationale: Prescribing principles 5 rights, DEA schedules I-V no medical high abuse I, prescription II-V, patient factors age renal hepatic pregnancy pharmacogenomics.
Per NURS8024 advanced pharmacology curriculum, including Katzung Pharmacology and Goodman & Gilman for graduate-level nursing and advanced practice students
exam 1 2026/2027.
Page 4 - NURS8024 Pharm Exam1 150Q 2026/2027
